2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2327

Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care
Abstract Number: 2328

The Correlation of Childhood Health Assessment Questionnaire with Disease Activity in Juvenile Idiopathic Arthritis
Abstract Number: 2329

Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Abstract Number: 2330

The Turkish Validity and Reliability of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)
Abstract Number: 2331

Agreement Between Patient’s and Physician’s Reported Bath Ankylosing Spondylitis Disease Activity Index in Patients with Axial Spondyloarthritis
Abstract Number: 2332

Deriving ‘population References’ of Health Utilities for Patients with Spondyloarthritis Based on the ASAS Health Index
Abstract Number: 2333

Patients’ Prioritization of Patient-Centered Education and Research Topics in Rheumatic Disease
Abstract Number: 2334

Proof of Concept Study of the Arthritis Health Journal: An Online Tool to Promote Self-Monitoring in People with Rheumatoid Arthritis (RA)
Abstract Number: 2335

How Much Does Fatigue Contribute to the Physician and Patient Global Estimates in Different Rheumatic Diseases? Analysis from Routine Care on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Abstract Number: 2336

Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2337

Depression, Bad Sleep Quality, and Functional Deficit Are Independently Associated with Persistent Fatigue in Arthritic Patients with Low Disease Activity Under Biological Dmards
Abstract Number: 2338

“It Was like No One Is Listening to Me”�: A Qualitative Study of the Lived Experiences of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance in Assessments of Disease Activity
Abstract Number: 2339

Impact of Abbvie’s Patient Support Program on Resource Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 2340

Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management
Abstract Number: 2341

Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].